175 completed, 14 terminated, 13 recruiting, 5 active not recruiting. 93 Phase 3, 63 Phase 2, 42 Phase 1, 13 Phase 4, 4 Not applicable.
Follow Otsuka Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Digital Patient-Reported Assessment in Older Adults With Acute Leukemia Digital Patient-Reported Assessment Pathway - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | Fundación para la Investigación Biosanitaria del Principado de Asturias | 20 | 2026-12-01 | 2026-10-07 |
| REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness Rejoyn, Cognitive Behavioral Therapy (CBT) exercises - Major Depressive Disorder (MDD) | Not yet recruiting | Yale University | 50 | 2026-09-01 | 2026-09-09 | |
| A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia SEP-363856 - Schizophrenia | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 100 | 2025-12-22 | 2026-01-14 |
| Kaempferol Absorption and Pharmacokinetics Evaluation Kaempferol - No Disease, Mitochondria Health | Not applicable | Recruiting | University of Pittsburgh | 120 | 2025-12-09 | 2026-03-23 |
| A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis OPA-15406, Vehicle - Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Co., Ltd. | 156 | 2025-10-01 | 2025-09-15 |
| LUPKYNIS Drug-use Results Survey Voclosporin (LUPKYNIS) - Lupus Nephritis | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 400 | 2025-09-17 | 2026-10-20 | |
| A Long-term Trial of EB-1020 in Pediatric Patients With ADHD EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose - Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 180 | 2025-09-16 | 2025-12-23 |
| A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose, Placebo - Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 315 | 2025-09-03 | 2025-12-23 |
| A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis OPA-15406, Vehicle - Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Co., Ltd. | 198 | 2025-09-01 | 2025-09-22 |
| A Pilot Study to Evaluate Equol and Its Effects on Menopausal Symptoms Experienced by Women in Singapore Consumption of soy protein bar - Menopause | Recruiting | Ang Seng Bin | 300 | 2025-07-02 | 2025-08-22 | |
| A Long-term Trial of EB-1020 in Adult Patients With ADHD EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 180 | 2025-06-25 | 2026-10-23 |
| Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 630 | 2025-04-30 | 2026-10-23 |
| REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia Brexpiprazole (Rexulti) - Alzheimer Disease | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 200 | 2025-04-17 | 2026-10-20 | |
| Software as a Medical Device for the Treatment of Patients With PTSD Software as a Medical Device - Post-Traumatic Stress Disorder, PTSD | Phase 2 / Phase 3 | Active not recruiting | Otsuka Medical Devices Co., Ltd. Japan | 52 | 2024-09-01 | 2026-10-19 |
| Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia OPC-34712FUM/ Brexpiprazole fumarate - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Co., Ltd. | 59 | 2023-10-03 | 2026-02-11 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders Brexpiprazole - Psychosis, Depression | Recruiting | Dr. Albert Kar-Kin Chung | 40 | 2023-07-01 | 2025-07-08 | |
| Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure. Samtasu for I.V. infusion - Heart Failure | Active not recruiting | Otsuka Pharmaceutical Co., Ltd. | 1600 | 2023-03-03 | 2026-06-22 | |
| A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia 180mg of ETC-1002(bempedoic acid) - Hyper-low-density Lipoprotein (LDL) Cholesterolemia | Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 130 | 2023-02-27 | 2026-02-20 |
| A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia 180mg of ETC-1002(bempedoic acid), Placebo - Hyper-low-density Lipoprotein (LDL) Cholesterolemia | Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 96 | 2023-02-13 | 2025-03-13 |
Showing 20 of 217. Sign in to see all of them.
Schizophrenia (25) · Depressive Disorder, Major (18) · Heart Failure (10) · Dermatitis, Atopic (9) · Dry Eye Syndromes (9) · Leukemia, Myeloid, Acute (9) · Psychotic Disorders (8) · Parkinson Disease (7) · Polycystic Kidney, Autosomal Dominant (7) · Fibrosis (6) · Mental Disorders (6) · Alcoholism (5) · Attention Deficit Disorder with Hyperactivity (5) · Migraine Disorders (5) · Alzheimer Disease (4)
Tolvaptan (30) · brexpiprazole (22) · Aripiprazole (20) · rebamipide (9) · rotigotine (8) · difamilast (7) · Cilostazol (6) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (4) · fremanezumab (4) · tetomilast (4) · (2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine (3) · Aspirin (3) · Busulfan (3) · emixustat (3) · nalmefene (3)
Japan (140) · United States (40) · South Korea (23) · Germany (8) · Taiwan (8) · Poland (7) · Singapore (7) · United Kingdom (7) · Canada (6) · China (6) · Australia (5) · France (5) · Italy (5) · Romania (5) · Spain (5)
Katsuhisa Saito (25) · Takehisa Matsumaru (13) · Kyoji Imaoka, Mr (12) · Nobuhito Sanada (11) · Osamu Sato (10) · Junichi Hashimoto, PhD (7) · Yasuhiko Fukuta, PhD (6) · Eiji Murakami (5) · Jun-ichi Hashimoto, PhD (4) · Takeshi Tsunoda (3)
PMID 29318278, PMID 30474567, PMID 31193334, PMID 34894307, PMID 37349694, PMID 39356039, PMID 17105757, PMID 21903984, PMID 22027579, PMID 25151571, PMID 33331670, PMID 34901863, PMID 35139816, PMID 35235720, PMID 37250503, PMID 42474330, PMID 19922880, PMID 20833591, PMID 21028753, PMID 22615190, PMID 23009892, PMID 23103551, PMID 24021518, PMID 24055212, PMID 24074484, PMID 24313916, PMID 24906029, PMID 24965202, PMID 24981319, PMID 25267759, PMID 25487817, PMID 25663351, PMID 25846031, PMID 25879416, PMID 26232241, PMID 27781135, PMID 27784751, PMID 27927736, PMID 28266765, PMID 28379536, PMID 28476132, PMID 28941259, PMID 28983800, PMID 29123425, PMID 29439650, PMID 29716784, PMID 30180806, PMID 30991969, PMID 31014270, PMID 31122494
2016 (2), 2015 (1), 2019 (1), KL2RR025006 (1), P30MH071478 (1), U01AI152980 (1)